[212Pb]VMT01 was observed to be safe, and no dose-limiting toxicities were observed at the two doses tested (3.0 and 5.0 mCi) Prolonged progression-free survival and tumor response were observed in heavily pretreated patients who received the low (3.0 mCi) dose of [212Pb]VMT01,...Read more
First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316 ACR-2316 was internally discovered and advanced in 15 months from initial lead to Phase 1 trial initiation uniquely enabled by AP3 ACR-2316 was...Read more
Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells Subcutaneous AK006 was well-tolerated with a favorable safety profile Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in...Read more
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis and on-demand treatment in eligible patients with hemophilia A or B without inhibitors In the U.S., HYMPAVZI is the first once-weekly subcutaneous prophylactic treatment...Read more
Approval is based on Phase III INAVO120 results, showing the ItovebiTM (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting This approval helps address an urgent unmet need in breast cancer for...Read more
Designation based on positive interim analysis of Phase 2b VANTAGE study FOSTER CITY, Calif. / Oct 10, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to volixibat as...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 21.37 2.35 | $932.06 |
| ZIVO Bioscience | 19.19 1,744.55 | $20.29 |
| Regeneron Pharmaceuticals | 16.65 1.67 | $1,015.67 |
| Penumbra | 10.61 5.51 | $203.19 |
| Elevance Health | 9.70 1.97 | $501.88 |
| Finch Therapeutics | 9.50 527.78 | $11.30 |
| argenx | 9.45 1.79 | $536.70 |
| Mettler-Toledo | 8.61 0.60 | $1,450.95 |
| Amgen | 7.34 2.29 | $328.35 |
| HCA Healthcare | 7.29 1.88 | $394.54 |
| Humana | 6.63 2.64 | $258.07 |
| Alnylam Pharmaceuticals | 5.70 2.05 | $284.32 |
| Krystal Biotech | 5.56 3.21 | $178.71 |
| Vertex Pharmaceuticals | 5.56 1.17 | $481.71 |
| Inspire Medical Systems | 5.39 2.62 | $210.83 |
| Waters | 5.33 1.51 | $357.97 |
| GeneDx | 5.00 9.09 | $60.00 |
| West Pharmaceutical | 4.84 1.67 | $294.91 |
| Company | Volume | Last Trade |
|---|---|---|
| Conduit Pharmaceuticals | 268,555,076 | $0.12 |
| Gritstone bio | 60,358,350 | $0.05 |
| Vyome | 36,361,564 | $0.22 |
| Pfizer | 24,987,796 | $29.16 |
| PacBio | 24,209,392 | $1.98 |
| Walgreens Boots Alliance | 19,779,370 | $9.21 |
| Universe Pharmaceuticals | 10,997,866 | $0.30 |
| CVS Health | 10,157,415 | $66.63 |
| ADMA Biologics | 8,683,676 | $17.15 |
| Clover Health | 7,730,256 | $4.07 |
| Geron | 7,321,288 | $4.33 |
| GSK | 6,851,669 | $38.83 |
| Merck | 6,612,669 | $109.73 |
| Tonix Pharmaceuticals | 6,423,438 | $0.15 |
| Moderna | 6,245,053 | $58.29 |
| Senseonics | 6,176,150 | $0.35 |
| Teva Pharmaceutical | 5,911,012 | $17.25 |
| Novavax | 5,744,262 | $12.53 |
| Roivant | 5,454,377 | $11.90 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
